Long-term ingestion of Touchi-extract, an α-glucosidase inhibitor, by borderline and mild type-2 diabetic subjects is safe and significantly reduces blood glucose levels

Nutrition Research

Volumn 23, Issue 6, 2003, Pages 713-722

  Fujita, Hiroyuki ^a   Yamagami, Tomohide ^a   Ohshima, Kazunori ^b  

^a Nippon Supplement Inc   (Japan)

^b Ohshima Clinic   (Japan)

Author keywords

Anti glycemic effect; Human non insulin dependent diabetic mellitus; Touchi extract; Type 2 diabetes; glucosidase inhibitor

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHINESE DRUG; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; PLACEBO; TOUCHI EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOD; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; JAPAN; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ILEX COOKII;

EID: 0038128514     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0271-5317(03)00028-9     Document Type: Article

References (26)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1606.
2. De Fronzo RA, Ferranini E. Insulin resistance a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atheroscrelotic cardiovascular disease. Diabetes Care 1991;14:173-194.
3. Toeller M. α-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 1994;24(suppl 3):31-35.
4. Clissold SP, Edwards CA. Preliminary review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential. Drugs 1988;35:214-243.
5. Saito N, Sakai H, Sekihara H, Yajima Y. Effect of an α -glucosidase inhibitor (voglibose), in combination with sulphonilureas, on glycaemic control in type 2 diabetes subjects. J Int Med Res 1998;26:219-232.
6. Rury RH, Robert CT, Carole AC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (U.K Prospective Diabetes Study 44). Diabetes Care 1999;22:960-964.
7. Fujita H, Yoshikawa M. LKPNM: a prodrug type ACE-inhibitory derived from fish protein. Immunopharmacology 1999;44:123-127.
8. Fujita H, Yokoyama K, Yoshikawa M. Classification and antihypertensive activity of angiotensin I-converting enzyme derived from food proteins. J Food Sci 2000;65:564-569.
9. Matsui T, Yoshimoto C, Osajima K, Oki T, Osajima Y. In vitro survey of α-glucosidase inhibitory food components. Biosci Biotechnol Biochem 1996;60:2019-2022.
10. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of α-glucosidase inhibitors from Tochu-cha (Encommia ulmoides). Biosci Biotechnol Biochem 1997;61:177-178.
11. Hansawasdi H, Kawabata J, Kasai T. α-amylase inhibitors from Rosell (Hibiscus sabdariffa Linn) Tea. Biosci Biotechnol Biochem 2000;64:1041-1043.
12. Morimoto T, Tanaka S, Miyazaki T, kodama T, Kitamura I, Inoue S. Effects of long-term ingestion of wheat albumin in mild non-insulin-dependent diabetes mellitus. J Jpn Soc Nutr Food Sci (in Japanese) 1999;52:293-300.
13. Fujita H, Yamagami T, Ohshima K. Fermented soybean-derived touchi extract with anti-glycaemic effect via α-glucosidase inhibitory action in rats and humans. J Nutr 2001;131:1211-1213.
14. Fujita H, Yamagami T, Ohshima K. Efficacy and Safety of Touchi Extract, an α-glucosidase inhibitor derived from fermented soybeans, in non-insuline-dependent diabetic mellitus. J Nutr Biochem 2001;12:351-356.
15. y mice. Life Sci 2001;70:219-227.
16. Miwa I, Okuda J, Horie T, Nakayama M. Inhibition of intestinal α-glucosidases and sugar absorption by flavones. Chem Pharm Bull 1986;34:838-844.
17. Expert committee on the diagnosis and classification of diabetes mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
18. Japan diabetes society Food-Calorie Conversion Table, 5th ed. (in Japanese). Tokyo, Japan: Bunkodo, 1993.
19. Hillerbrand I, Boehm K, Frank G, Fink H, Berchtoid P. The effects of the α -glucosidase inhibitor BAY g5421 (acarbose) on meal stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Res Exp Med 1979;175:81-86.
20. Hillerbrand I, Boehm K, Frank G, Fink H, Berchtoid P. The effects of the α-glucosidase inhibitor BAY g5421 (acarbose) on postprandial glucose, serum insulin and triglyceride levels: dose-time-responserelationship in man. Res Exp Med 1979;175:87-94.
21. Homma Y, Irie N, Yano Y, Nakaya N, Goto Y. Changes in plasma lipoprotein levels during medication with a glucosidase-hydrolase inhibitor (acarbose). Tokai Journal of Experimental and Clinical Medicine 1982;7:393-396.
22. Nestel PJ, Bazelmans J, Reardon MF, Boston RC. Lower triglyceride production during carbohydrate-rich diet through acarbose, α-glucosidase hydrolase inhibitor. Diabete et Metabolism 1985;11:316-317.
23. Harano Y, Suzuki M, Koyama Y, Kanda M, Yasuda S, Suzuki K, Takamizawa I. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular disease. J Diabetes and its Complications 2002;16:19-23.
24. Malaguarnera M, Giugno I, Panebianco MP, Pistone G. Beneficial effects of acarbose on familiar hypertriglyceridemias. Clin Pharmacol Ther 1998;36:441-445.
25. Matsuo T, Okada H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128), on obesity and diabetes. Am J Clin Nutr 1992;55(suppl 1):314-317.
26. Friedman L, Brandon DL. Nutritional and health benefits of soy proteins. J Agric Food Chem 2001;49:1069-1086.